FDA approves Obagi saypha ChIQ hyaluronic acid gel for cheek augmentation

The FDA has approved Obagi saypha ChIQ injectable hyaluronic acid gel for cheek augmentation and the correction of midface contour deficiencies in adults aged 21 and older. Developed and manufactured by Austria-based Croma-Pharma, the gel will be commercialized in the United States by Obagi Medical, which is owned by Waldencast. This regulatory milestone marks the second US approval from Croma-Pharma's saypha portfolio, following the September 2025 approval of the Obagi saypha MagIQ formulation.

For your practice, this means another major European player is entering the domestic midface market. Croma-Pharma brings a high-volume manufacturing pedigree to the table, having produced over 130 million syringes globally. The introduction of ChIQ provides a new clinical alternative for patients seeking volume restoration in the malar region, backed by an established international track record. As Obagi Medical integrates this product alongside MagIQ, clinicians can expect structured commercial rollouts. It is worth watching how they position this portfolio against dominant US market incumbents, particularly regarding packaging, pricing, and clinical training opportunities.

Source: Business Wire, https://www.businesswire.com/news/home/20260701831845/en/Croma-Pharma-Announces-FDA-Approval-of-Obagi-saypha%C2%AE-ChIQ%E2%84%A2-in-the-United-States